SSelectStock

ZOTAZota Health Care LImited

Pharma · Biotechnology · NSE · as of 2026-09-11 (delayed ~30 min in market hours)

Zota Health Care Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company offers generic drugs, health supplements, over-the-counter products, wellness and ayurvedic products, and nutraceutical products. It provides various medicines for chronic ailments, such as diabetes, cardiac, and thyroid disorders. The company operates its retail stores under the DAVAINDIA name. Zota Health Care Limited was founded in 1995 and is headquartered in Surat, India.

1,087.20
1.12%
31Weak

Mkt Cap
₹3,298 Cr
P/E
P/B
5.4
Div Yield
0.09%
52W High
₹1,740.00
52W Low
₹1,022.00

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)3,297.80
P/E
P/B5.43
PEG
ROE %-10.70
ROCE %-6.60
Debt / Equity0.39
EPS-30.09
Revenue Growth %67.60
Profit Growth %-31.10
Dividend Yield %0.09
Promoter Holding %0.00
FII Holding %1.44
DII Holding %
Beta0.38

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

None of the 16 pattern scanners currently detects a setup on ZOTA — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.

AVOIDConviction 71%

Why avoid

  • Overall evidence is weak (AlgoScore 31/100)
  • Profit growth: -31.1% YoY
  • ROE: -10.7%
  • Price vs EMA21: below
  • Price vs SMA50: below

Bull case

  • Revenue growth: 67.6% YoY
  • Debt/Equity: 0.39
  • MACD: bullish
  • Trend strength (ADX): 26

Bear case

  • Profit growth: -31.1% YoY
  • ROE: -10.7%
  • Price vs EMA21: below
  • Price vs SMA50: below

Key risks

  • Weak fundamentals — technical strength may not sustain
  • Momentum is fading versus the broader market
  • Profit growth: -31.1% YoY
  • ROE: -10.7%

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹1,087.20
Stop Loss
₹1,011.78
risk 6.9%
Target 1 (1.5R)
₹1,200.33
+10.4%
Target 2 (3R)
₹1,313.46
+20.8%
Support (20d)
₹1,022.00
Resistance (52w)
₹1,740.00
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹75.42/share
ATR (volatility)
₹42.47
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹42.47). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental31
Technical32
Momentum17
Risk (safety)52

Peers — Pharma

CORONA 1.60%
87
GRANULES 1.12%
81
LAURUSLABS 1.23%
79
KPL 3.75%
79
DIVISLAB 1.23%
79
CAPLIPOINT 1.45%
78